Study of METTL3 inhibitor for urinary tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug that may help your body's immune system fight urinary system tumors better. It is for people who have surgery to remove their tumor, and researchers will study tissue from the surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a urinary system tumor confirmed by a biopsy or other test.
- You are scheduled for surgery to remove the tumor.
- The tissue removed during surgery can be used for testing.
- You are between 18 and 75 years old.
- You are willing to sign a consent form and participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LY4052031 for people with advanced or metastatic cancers, especially bladder cancer. The drug aims to slow or stop tumor growth. Doctors will check if it is safe and how well it works.
This trial studies a redesigned surgical instrument used during bladder tumor removal, to see if it can improve how the removed tissue samples are collected. It may help future patients by supporting better study of bladder tissue during cancer care.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
This trial tests a new drug combination for advanced bladder or urinary tract cancer that has not been treated before. The study compares a standard chemotherapy plus immunotherapy with and without an extra drug that may reduce side effects.
This study looks at tumor and blood samples from people with muscle-invasive bladder cancer to find markers that help predict how the disease will progress. It aims to improve personalized treatment for those with this specific stage of bladder cancer.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.